Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19023739 | Prostate | BPH | negative regulation of mRNA catabolic process | 21/3107 | 63/18723 | 8.71e-04 | 5.62e-03 | 21 |
GO:00450707 | Prostate | BPH | positive regulation of viral genome replication | 12/3107 | 30/18723 | 1.94e-03 | 1.10e-02 | 12 |
GO:00482559 | Prostate | BPH | mRNA stabilization | 18/3107 | 56/18723 | 3.12e-03 | 1.63e-02 | 18 |
GO:00162392 | Prostate | BPH | positive regulation of macroautophagy | 19/3107 | 63/18723 | 5.36e-03 | 2.49e-02 | 19 |
GO:00434897 | Prostate | BPH | RNA stabilization | 19/3107 | 65/18723 | 7.73e-03 | 3.39e-02 | 19 |
GO:00973062 | Prostate | BPH | cellular response to alcohol | 25/3107 | 93/18723 | 8.12e-03 | 3.53e-02 | 25 |
GO:001603219 | Prostate | Tumor | viral process | 155/3246 | 415/18723 | 7.20e-23 | 1.12e-19 | 155 |
GO:000641317 | Prostate | Tumor | translational initiation | 66/3246 | 118/18723 | 2.57e-21 | 2.66e-18 | 66 |
GO:000641719 | Prostate | Tumor | regulation of translation | 161/3246 | 468/18723 | 1.55e-19 | 8.74e-17 | 161 |
GO:190331117 | Prostate | Tumor | regulation of mRNA metabolic process | 111/3246 | 288/18723 | 6.66e-18 | 2.30e-15 | 111 |
GO:001905819 | Prostate | Tumor | viral life cycle | 117/3246 | 317/18723 | 4.10e-17 | 1.18e-14 | 117 |
GO:000989619 | Prostate | Tumor | positive regulation of catabolic process | 155/3246 | 492/18723 | 5.62e-15 | 8.52e-13 | 155 |
GO:000644615 | Prostate | Tumor | regulation of translational initiation | 44/3246 | 79/18723 | 1.37e-14 | 1.89e-12 | 44 |
GO:003425018 | Prostate | Tumor | positive regulation of cellular amide metabolic process | 68/3246 | 162/18723 | 1.42e-13 | 1.63e-11 | 68 |
GO:000640217 | Prostate | Tumor | mRNA catabolic process | 87/3246 | 232/18723 | 1.56e-13 | 1.73e-11 | 87 |
GO:003133119 | Prostate | Tumor | positive regulation of cellular catabolic process | 134/3246 | 427/18723 | 5.54e-13 | 5.84e-11 | 134 |
GO:004572718 | Prostate | Tumor | positive regulation of translation | 59/3246 | 136/18723 | 1.06e-12 | 9.98e-11 | 59 |
GO:000640117 | Prostate | Tumor | RNA catabolic process | 94/3246 | 278/18723 | 1.77e-11 | 1.25e-09 | 94 |
GO:190165418 | Prostate | Tumor | response to ketone | 70/3246 | 194/18723 | 2.69e-10 | 1.48e-08 | 70 |
GO:004594712 | Prostate | Tumor | negative regulation of translational initiation | 15/3246 | 19/18723 | 7.16e-09 | 2.75e-07 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP1 | SNV | Missense_Mutation | novel | c.1336N>T | p.Arg446Cys | p.R446C | Q6PKG0 | protein_coding | deleterious(0.01) | possibly_damaging(0.707) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
LARP1 | SNV | Missense_Mutation | | c.2636N>T | p.Arg879Leu | p.R879L | Q6PKG0 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
LARP1 | SNV | Missense_Mutation | | c.2360N>T | p.Cys787Phe | p.C787F | Q6PKG0 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | | c.498N>C | p.Gln166His | p.Q166H | Q6PKG0 | protein_coding | tolerated(0.06) | benign(0.048) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LARP1 | SNV | Missense_Mutation | | c.1789N>A | p.Glu597Lys | p.E597K | Q6PKG0 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | rs775862354 | c.253C>T | p.Arg85Cys | p.R85C | Q6PKG0 | protein_coding | deleterious(0) | possibly_damaging(0.809) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | | c.1676N>T | p.Asp559Val | p.D559V | Q6PKG0 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | novel | c.238N>A | p.Ala80Thr | p.A80T | Q6PKG0 | protein_coding | tolerated(0.08) | possibly_damaging(0.677) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
LARP1 | insertion | Nonsense_Mutation | novel | c.768_769insTGAAGTC | p.Arg257Ter | p.R257* | Q6PKG0 | protein_coding | | | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LARP1 | insertion | Frame_Shift_Ins | novel | c.815_816insCCCAGAGAGAAACTGGCTTC | p.Arg273ProfsTer38 | p.R273Pfs*38 | Q6PKG0 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |